middle.news

How Amplia’s Narmafotinib Is Shaping the Future of Pancreatic Cancer Treatment

1:14am on Monday 2nd of June, 2025 AEST Healthcare
Read Story

How Amplia’s Narmafotinib Is Shaping the Future of Pancreatic Cancer Treatment

1:14am on Monday 2nd of June, 2025 AEST
Key Points
  • ACCENT Phase 2a trial fully enrolled two months early with 55 patients
  • 15 confirmed partial responses demonstrating promising efficacy
  • Initiation of US-based FOLFIRINOX combination trial underway
  • FDA Fast Track Designation granted for narmafotinib
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE